Fig. 5From: Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibitionCellular and molecular responses to tepotinib, irradiation or their combination. A,B. Syngeneic mice were intracranially implanted with SMA-560 glioma cells and treated daily with 100 mg/kg tepotinib from day 6 on or solvent, or with a single dose of 12 Gy on day 7, or in combination. A. Brains from three pre-randomized animals per group were stained for H&E (upper row), Ki-67 (middle row) or CD31 (lower row). Sections were counterstained with hematoxylin (blue). Quantification of immunoreactivity is shown in the right panels (n = 3, * p < 0.05, t-test, compared with control). B. Tumor lysates pooled from 2 prerandomized animals per group were analysed by proteome profiler array. Fold-changes indicate down-regulation (left) or up-regulation (right) versus control tumors. A difference down or up of twofold versus control was used as cut-off to assign a target to any group. Not all groups shown in Table S1 are included hereBack to article page